Camrelizumab for returning brain lymphoma after prior treatment
Treatments studied
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This trial studies camrelizumab (an immune medicine) for primary CNS lymphoma that has come back after standard treatment. It aims to shrink the lymphoma seen on MRI and help control the disease with a new immune-based approach.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult (age over 18).
- Your lymphoma started in the brain/central nervous system and was proven on tissue biopsy.
- Your cancer came back after first treatment with methotrexate (with or without radiation), confirmed by MRI.
- Your MRI shows a measurable tumor spot larger than 10×10 mm.
- Your blood counts and organ labs must be strong enough (for example, white blood cells, platelets, and hemoglobin above set cutoffs).
- You can’t have recent other anti-cancer treatments, and you must not have had anti–PD-1/PD-L1/PD-L2 drugs before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of the immunotherapy drug pembrolizumab (Keytruda) with standard chemotherapy for people newly diagnosed with primary CNS lymphoma. The goal is to see if adding pembrolizumab can improve outcomes compared to chemotherapy alone.
This trial tests a combination of two drugs, tafasitamab and lenalidomide, for people whose central nervous system lymphoma has come back. The goal is to see if this treatment can help shrink the cancer or slow its growth.
This trial tests a combination of orelabrutinib, rituximab, and methotrexate in people with newly diagnosed primary CNS lymphoma (a lymphoma mainly in the brain/spinal fluid). The goal is to see how well the treatment works and how safely it can be given.
This trial tests whether adding an immunotherapy drug to standard chemotherapy helps people with newly diagnosed primary central nervous system lymphoma (a rare brain cancer) live longer without the disease getting worse. It compares the combination to chemotherapy alone.
This Phase 2 study tests a combination treatment to shrink primary central nervous system lymphoma that starts in the brain, spinal cord, meninges, or eye. It may help patients who have not had anti-cancer treatment yet, but it requires specific cancer type and health conditions.
This trial tests a combination of drugs for people newly diagnosed with primary central nervous system lymphoma (a rare type of brain lymphoma). The treatment aims to shrink tumors and improve outcomes.
Hear when a new Primary Central Nervous System Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.